The profound synergy observed between PARP and BET inhibition in preclinical studies of homologous recombination‐proficient breast and ovarian cancers has catalyzed clinical investigations to validate these findings in patient populations, opening a promising new chapter in targeted cancer therapy.274, 275. This evidence concerns the gene PARP1 and cancer.